Posts Tagged ‘Alzheimer's drug’
Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab
Study questions benefit of new Alzheimer’s drug (UGA Today): Last summer, the U.S. Food and Drug Administration fully approved the first drug shown to slow the progress of Alzheimer’s. But new research from the University of Georgia suggests that patients and caregivers may not experience any benefit from the drug in their daily lives. The drug, Leqembi,…
Read MoreCMS: anti-amyloid drug Leqembi (lecanemab) doesn’t meet the “reasonable and necessary” standard required for wider Medicare coverage
CMS Sticks to Sharply Limited Coverage of New Alzheimer’s Drug, Leqembi (Managed Healthcare Executive): For now, CMS (Note: Centers for Medicare & Medicaid Services) is sticking to the coverage decision it made for Aduhelm (aducanumab) and applying it Leqembi (lecanemab). The decision limits Medicare coverage of the two Alzheimer disease’s drugs to Medicare beneficiaries who…
Read MoreCould I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring eight timely scientific and industry news plus a few fun teasers to appreciate our unique human brains. #1. Could I be wrong? Exploring research on cognitive bias, curiosity, intellectual humility, and lifelong learning “None of us thinks that our beliefs and attitudes are incorrect; if we…
Read MoreAmyloid-related imaging abnormalities (ARIA) found in approximately 40% of patients taking “Alzheimer’s drug” Aduhelm
Study: Biogen’s Aduhelm Caused Brain Swelling in Over One-Third of Study Participants (BioSpace): Attention is being focused on a side effect of Biogen’s Alzheimer’s drug, Aduhelm (aducanumab). Even before its controversial approval on June 7, there were cases of amyloid-related imaging abnormalities (ARIA‑E), or cerebral edema, observed in the trials.
Read MoreOn cognitive reframing and biases, stress, mental health tech, Aduhelm backlash, Britney Spears, and more
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring this time nine scientific reports and industry developments to help promote lifelong brain and mental health. #1. To lower stress levels and improve problem-solving, practice cognitive reframing instead of venting “… venting likely doesn’t soothe anger as much as augment it. That’s because encouraging people to…
Read MoreVeterans Affairs won’t cover Biogen’s new “Alzheimer’s drug” given concerns over safety and lack of evidence
VA Health System Won’t Cover Biogen’s Alzheimer’s Drug (The Wall Street Journal): The Department of Veterans Affairs won’t cover Biogen Inc.’s new Alzheimer’s drug, the latest rebuke of the controversial treatment since it was approved earlier this summer. The VA decided not add the drug, called Aduhelm, to its formulary list of available medicines because…
Read More